Drug Price Trends for NDC 69584-0611

Average Pharmacy Cost for 69584-0611

Drug Name	NDC	Price/Unit ($)	Unit	Date
METHOCARBAMOL 500 MG TABLET	69584-0611-90	0.03725	EACH	2026-03-18
METHOCARBAMOL 500 MG TABLET	69584-0611-50	0.03725	EACH	2026-03-18
METHOCARBAMOL 500 MG TABLET	69584-0611-10	0.03725	EACH	2026-03-18

Best Wholesale Price for NDC 69584-0611

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
METHOCARBAMOL 500MG TAB	Golden State Medical Supply, Inc.	69584-0611-10	100	6.60	0.06600	2023-06-15 - 2028-06-14	FSS
METHOCARBAMOL 500MG TAB	Golden State Medical Supply, Inc.	69584-0611-10	100	7.05	0.07050	2023-06-23 - 2028-06-14	FSS
METHOCARBAMOL 500MG TAB	Golden State Medical Supply, Inc.	69584-0611-50	500	34.43	0.06886	2023-06-16 - 2028-06-14	FSS

Market Analysis and Price Projections for NNDC: 69584-0611

Last updated: February 19, 2026

This report analyzes the market landscape and projects future pricing for the pharmaceutical product with National Drug Code (NDC) 69584-0611. The analysis incorporates current market penetration, competitive landscape, patent status, and regulatory considerations to forecast price trajectories over the next five years.

What is the Current Market Status of NDC: 69584-0611?

NDC 69584-0611 is a prescription medication indicated for the treatment of [Insert Approved Indication(s) Here]. As of Q4 2023, the drug has achieved [Insert Market Penetration Percentage]% market share within its therapeutic class. This penetration is driven by its [List 1-2 Key Differentiating Factors, e.g., efficacy, safety profile, administration route].

The primary therapeutic class for NDC 69584-0611 is [Insert Therapeutic Class, e.g., Antihypertensives, Oncology, Diabetes Management]. Competitors within this class include products such as [List 2-3 Key Competitor NDCs or Brand Names]. The total market size for this therapeutic class is estimated at [Insert Market Size in USD] billion, with an anticipated compound annual growth rate (CAGR) of [Insert Therapeutic Class CAGR]% over the next five years, according to data from [Cite Source 1].

Current pricing for NDC 69584-0611, based on average wholesale price (AWP) for a standard unit ([Specify Unit, e.g., 30-day supply, 100mg tablet]), is approximately $[Insert Current AWP in USD]. This price point positions it [Compare to Competitors, e.g., above, below, in line with] its direct competitors. Reimbursement coverage for NDC 69584-0611 is robust, with [Insert Percentage]% of major commercial payers and [Insert Percentage]% of Medicare Part D plans offering coverage, as reported by [Cite Source 2].

What is the Patent and Exclusivity Landscape for NDC: 69584-0611?

The patent and regulatory exclusivity status of NDC 69584-0611 is critical to its pricing power and future market dynamics. The primary patent protecting the active pharmaceutical ingredient (API) is U.S. Patent No. [Insert Patent Number], which expires on [Insert Expiration Date]. This patent is owned by [Insert Patent Owner].

Secondary patents related to formulation, method of use, or manufacturing processes include U.S. Patent Nos. [Insert Patent Numbers, if applicable]. These patents expire on [Insert Expiration Dates, if applicable].

In addition to patent protection, NDC 69584-0611 benefits from [Specify Regulatory Exclusivity, e.g., New Chemical Entity (NCE) exclusivity, Orphan Drug Exclusivity (ODE), Pediatric exclusivity]. NCE exclusivity, granted by the U.S. Food and Drug Administration (FDA), extends until [Insert Exclusivity Expiration Date]. ODE status, if applicable, was granted on [Insert ODE Grant Date] and expires on [Insert ODE Expiration Date]. Pediatric exclusivity, if applicable, extends the market exclusivity until [Insert Pediatric Exclusivity Expiration Date].

As of [Current Date], there are [Insert Number] Abbreviated New Drug Applications (ANDAs) filed with the FDA seeking approval for generic versions of NDC 69584-0611. Of these, [Insert Number] have received tentative approval and [Insert Number] have received final approval. The first generic competitor is anticipated to enter the market on or around [Insert Projected Generic Entry Date], based on [Cite Source 3].

How Do Manufacturing Costs and Supply Chain Dynamics Affect Pricing?

Manufacturing costs for NDC 69584-0611 are influenced by the complexity of the API synthesis, the cost of raw materials, and the scale of production. The primary API is synthesized through a [Describe Synthesis Complexity, e.g., multi-step chemical process, fermentation process]. Key raw materials include [List 1-2 Key Raw Materials], whose global market prices have seen [Describe Price Trend, e.g., increased by 5% year-over-year, remained stable] in the past year, according to [Cite Source 4].

The current manufacturing of NDC 69584-0611 is primarily undertaken by [Insert Manufacturer Name(s) or specify if contract manufacturing] at facilities located in [Insert Geographic Locations]. The consolidated annual production volume for the drug is approximately [Insert Production Volume, e.g., 1 million units, 500,000 bottles].

The supply chain involves [Describe Key Supply Chain Stages, e.g., API manufacturing, formulation, packaging, distribution]. Lead times for API procurement are typically [Insert Lead Time, e.g., 6-8 weeks]. The current supply chain is considered [Describe Supply Chain Stability, e.g., stable, susceptible to disruptions due to geopolitical events, reliant on single-source suppliers for specific intermediates]. Recent disruptions in the [Specify Industry, e.g., global shipping, specialty chemical markets] have [Describe Impact, e.g., added 10% to shipping costs, caused minor delays of 1-2 weeks].

The cost of goods sold (COGS) for NDC 69584-0611 is estimated at [Insert COGS Percentage of AWP or specific USD amount] of the AWP. Any significant fluctuations in raw material costs or supply chain disruptions have the potential to [Describe Impact on Price, e.g., increase COGS by 2-3%, necessitate price adjustments within 6 months].

What is the Competitive Landscape and its Impact on Pricing?

The competitive landscape for NDC 69584-0611 is characterized by [Describe Competitive Intensity, e.g., moderate competition, a highly concentrated market, fragmented with numerous smaller players]. As previously noted, key competitors include [Reiterate 2-3 Key Competitor NDCs or Brand Names].

A comparative analysis of pricing strategies reveals the following:

Product Name/NDC	Indication	Current AWP (30-day supply)	Market Share (%)	Key Differentiation
NDC: 69584-0611	[Insert Approved Indication(s) Here]	$[Insert Current AWP in USD]	[Insert Market Penetration Percentage]%	[List 1-2 Key Differentiating Factors]
[Competitor 1 NDC]	[Insert Competitor 1 Indication]	$[Insert Competitor 1 AWP]	[Insert Competitor 1 Market Share]%	[Insert Competitor 1 Differentiation]
[Competitor 2 NDC]	[Insert Competitor 2 Indication]	$[Insert Competitor 2 AWP]	[Insert Competitor 2 Market Share]%	[Insert Competitor 2 Differentiation]
[Competitor 3 NDC]	[Insert Competitor 3 Indication]	$[Insert Competitor 3 AWP]	[Insert Competitor 3 Market Share]%	[Insert Competitor 3 Differentiation]

Source: [Cite Source 5]

The entry of generic competitors will exert significant downward pressure on the price of NDC 69584-0611. Historically, branded drugs experience an average price decline of [Insert Percentage Range, e.g., 40-60%] in the first year following generic entry, as reported by [Cite Source 6]. The launch of approved generics for NDC 69584-0611 is projected to reduce its AWP by approximately [Insert Projected Price Reduction Percentage]% within 12 months of the first generic market entry.

Market dynamics also include the influence of Pharmacy Benefit Managers (PBMs) and formulary placement. NDC 69584-0611 currently holds a [Describe Formulary Status, e.g., preferred, non-preferred, tier 2] status on [Insert Percentage]% of major commercial formularies. This favorable placement contributes to its current market share but may be subject to re-evaluation upon generic availability, potentially leading to formulary shifts and impacting rebate negotiations.

What Are the Projected Price Trajectories for NDC: 69584-0611?

The pricing of NDC 69584-0611 over the next five years will be primarily shaped by the expiration of patent exclusivity, the introduction of generic competition, and ongoing market access strategies.

Projected AWP (USD) for NDC: 69584-0611 (Per 30-day Supply):

• 2024: $[Insert 2024 Projected AWP]
• 2025: $[Insert 2025 Projected AWP]
• 2026: $[Insert 2026 Projected AWP]
• 2027: $[Insert 2027 Projected AWP]
• 2028: $[Insert 2028 Projected AWP]

Key Factors Influencing Projections:

• Pre-Generic Entry (2024): The price is expected to remain relatively stable, with potential minor adjustments of [Insert Percentage Range, e.g., 1-2%] due to inflation and minor cost increases.
• Post-Generic Entry (2025-2026): Upon the introduction of the first generic competitor in [Insert Projected Generic Entry Year], the AWP for the branded product is projected to decline by [Insert Projected Price Reduction Percentage]%. This decline will be partially offset by ongoing formulary negotiations and potential value-based agreements, which may preserve a portion of the price for specific patient populations.
• Sustained Generic Competition (2027-2028): As more generic manufacturers enter the market, further price erosion is anticipated. The branded product may transition to a niche market strategy, focusing on specific patient segments or geographical regions where its value proposition remains strong. The AWP is projected to stabilize at approximately [Insert Stabilized AWP in USD] by 2028, representing a [Insert Total Percentage Reduction]% decrease from current levels.

Rebate and Discount Structures:

The effective net price of NDC 69584-0611 will be lower than the AWP due to rebate agreements with payers and PBMs. Prior to generic entry, net prices are estimated to be [Insert Percentage Range, e.g., 15-25%] below AWP. Post-generic entry, net prices are expected to converge with generic pricing, potentially with residual rebates for preferred formulary status, leading to net prices that are [Insert Percentage Range, e.g., 50-70%] below the current AWP by 2028.

Key Takeaways

• NDC 69584-0611 holds a significant market share within its therapeutic class, driven by [List 1-2 Key Differentiating Factors].
• The drug's patent and exclusivity protection expires on [Insert Latest Expiration Date], with the first generic entry anticipated around [Insert Projected Generic Entry Date].
• Manufacturing costs are influenced by API synthesis complexity and raw material price volatility.
• The competitive landscape will intensify significantly with the advent of generic alternatives.
• Projected AWP for NDC 69584-0611 is expected to decrease by approximately [Insert Total Percentage Reduction]% by 2028, with the most substantial decline occurring post-generic entry.

Frequently Asked Questions

1. When is the primary patent for NDC: 69584-0611 set to expire? The primary patent, U.S. Patent No. [Insert Patent Number], expires on [Insert Expiration Date].

2. What is the estimated market share of NDC: 69584-0611 as of the latest available data? As of Q4 2023, the drug has achieved [Insert Market Penetration Percentage]% market share within its therapeutic class.

3. What is the anticipated percentage decline in AWP for NDC: 69584-0611 following the first generic entry? The AWP is projected to decline by approximately [Insert Projected Price Reduction Percentage]% within 12 months of the first generic market entry.

4. Are there any pending Paragraph IV challenges against the patents protecting NDC: 69584-0611? [State Yes/No and provide brief detail if applicable, e.g., "No paragraph IV challenges have been publicly disclosed as of [Current Date]." or "Yes, [Number] Paragraph IV challenges have been filed by [Generic Manufacturer(s)]."]

5. What is the estimated production volume of NDC: 69584-0611 annually? The consolidated annual production volume is approximately [Insert Production Volume, e.g., 1 million units, 500,000 bottles].

Citations

1. [Full Citation for Therapeutic Class Market Data]
2. [Full Citation for Reimbursement Coverage Data]
3. [Full Citation for Generic Entry Projections]
4. [Full Citation for Raw Material Market Prices]
5. [Full Citation for Competitive Landscape Data]
6. [Full Citation for Generic Price Erosion Historical Data]